BiotechTube

ASP2151 + Valacyclovir hydrochloride

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Herpes Zoster

Conditions

Herpes Zoster

Trial Timeline

Nov 13, 2007 → Sep 1, 2008

NCT ID
NCT00487682

About ASP2151 + Valacyclovir hydrochloride

ASP2151 + Valacyclovir hydrochloride is a phase 2 stage product being developed by Astellas Pharma for Herpes Zoster. The current trial status is completed. This product is registered under clinical trial identifier NCT00487682. Target conditions include Herpes Zoster.

What happened to similar drugs?

8 of 20 similar drugs in Herpes Zoster were approved

Approved (8) Terminated (1) Active (11)
✅Zoster Vaccine, Live + Comparator: placeboMerckApproved
✅Zoster Vaccine LiveMerckApproved
✅ZOSTAVAX®MerckApproved
✅FamciclovirNovartisApproved
✅Famciclovir + PlaceboNovartisApproved
✅FamciclovirNovartisApproved
✅FamciclovirNovartisApproved

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00487682Phase 2Completed

Competing Products

20 competing products in Herpes Zoster

See all competitors
ProductCompanyStageHype Score
mRNA-1608ModernaPhase 2
0
mRNA-1468ModernaPhase 2
0
ASP2151 + PlaceboAstellas PharmaPhase 1
29
ASP2151 + valacyclovir + PlaceboAstellas PharmaPhase 2
35
Dolutegravir 50 mg tablet + Dolutegravir 50 mg oral granulesShionogiPhase 1
29
GSK1349572 + EfavirenzShionogiPhase 1
29
Zoster Vaccine, Live + Comparator: PlaceboMerckPhase 2
35
Comparator: V212 + Comparator: PlaceboMerckPhase 1
29
Zoster Vaccine, LiveMerckPhase 3
40
V212 + PlaceboMerckPhase 3
40
zoster vaccine live (ZOSTAVAX™) + Comparator: PlaceboMerckPhase 3
40
ZOSTAVAXMerckPhase 3
40
Zoster Vaccine, Live (AMP) + Zoster Vaccine, LiveMerckPhase 3
40
V212 + PlaceboMerckPhase 2
35
V212 + Matching placeboMerckPhase 3
40
V212 Lot 1 + V212 Lot 2 + V212 Lot 3MerckPhase 3
32
HSV 2 Formulation 1 + HSV 2 Formulation 2 + HSV 2 Formulation 3 + HSV 2 Formulation 4 + HSV 2 Formulation 5 + HSV 2 Formulation 6 + Sodium Chloride 0.9%MerckPhase 1
21
V212 + PlaceboMerckPhase 1
29
Zoster Vaccine, Live, (Oka-Merck), ZOSTAVAX™ + Comparator: placebo (concomitant-vaccine matched) + Pneumococcal Vaccine, Polyvalent (23-valent), PNEUMOVAX™ 23MerckPhase 3
40
ZOSTAVAX™ (Zoster Vaccine Live) Full Dose Subcutaneous + ZOSTAVAX™ (Zoster Vaccine Live) 1/3 Dose Subcutaneous + ZOSTAVAX™ (Zoster Vaccine Live) Full Dose Intradermal + ZOSTAVAX™ (Zoster Vaccine Live) Partial Doses Intradermal + Full Dose Intradermal Placebo + Intradermal PlaceboMerckPhase 1
29